-
Table of Contents
Patents and Formulations History of Trestolone Enantato
Trestolone enantato, also known as MENT enanthate, is a synthetic androgen and anabolic steroid that has gained significant attention in the world of sports pharmacology. It is a modified form of the hormone nandrolone, with a longer ester attached, allowing for a slower release into the body. This unique characteristic has made it a popular choice among athletes and bodybuilders looking to enhance their performance and physique.
History of Trestolone Enantato
The history of trestolone enantato dates back to the 1960s when it was first synthesized by the pharmaceutical company Organon. It was initially developed as a potential male contraceptive, but its androgenic and anabolic properties were soon discovered, leading to its use in the treatment of various medical conditions such as hypogonadism and wasting syndromes.
However, due to its potent anabolic effects, trestolone enantato quickly caught the attention of the bodybuilding community, and it was soon being used off-label for performance enhancement. This led to its classification as a controlled substance in many countries, and its use in sports was banned by major sporting organizations.
Patents of Trestolone Enantato
Despite its controversial history, trestolone enantato has been the subject of numerous patents over the years. In 1975, Organon filed a patent for trestolone enantato as a male contraceptive, which was later granted in 1981 (US Patent 4,259,125). In 1997, a patent was filed for the use of trestolone enantato in the treatment of male hypogonadism (US Patent 5,648,377). And in 2003, a patent was granted for the use of trestolone enantato in the treatment of wasting syndromes (US Patent 6,541,490).
More recently, in 2014, a patent was filed for a transdermal formulation of trestolone enantato, which was granted in 2017 (US Patent 9,655,945). This formulation allows for the delivery of trestolone enantato through the skin, providing a more convenient and discreet method of administration.
Formulations of Trestolone Enantato
Trestolone enantato is available in various formulations, including oral, injectable, and transdermal. The most common form is the injectable version, which is typically administered once or twice a week. The oral form, on the other hand, has a shorter half-life and needs to be taken daily to maintain stable blood levels.
The transdermal formulation, as mentioned earlier, is a relatively new development and offers a more convenient and painless method of administration. It is applied to the skin and absorbed into the bloodstream, bypassing the liver and reducing the risk of liver toxicity.
Pharmacokinetics and Pharmacodynamics of Trestolone Enantato
Like other anabolic steroids, trestolone enantato works by binding to androgen receptors in the body, stimulating protein synthesis and promoting muscle growth. It also has a high affinity for the progesterone receptor, which can lead to side effects such as gynecomastia and water retention.
Studies have shown that trestolone enantato has a longer half-life compared to other anabolic steroids, with a reported half-life of 8-12 days (Kicman et al. 2015). This means that it can remain active in the body for an extended period, allowing for less frequent dosing and a more stable blood level.
Furthermore, trestolone enantato has a high anabolic to androgenic ratio, making it a potent muscle builder with minimal androgenic side effects. This has made it a popular choice among athletes and bodybuilders looking to gain lean muscle mass and improve their physical performance.
Real-World Examples
The use of trestolone enantato in sports has been a topic of controversy for many years. However, there have been several real-world examples of its use and its effects on athletic performance.
In 2016, the International Olympic Committee (IOC) reported that a weightlifter from Kyrgyzstan had tested positive for trestolone enantato during the Rio Olympics (IOC 2016). This led to the athlete being disqualified and stripped of their medal.
Another example is the case of American sprinter, Justin Gatlin, who tested positive for trestolone enantato in 2006 and was subsequently banned from competing for four years (BBC 2006). Gatlin’s case sparked a debate about the use of performance-enhancing drugs in sports and the effectiveness of drug testing protocols.
Expert Opinion
Despite its controversial history and use in sports, trestolone enantato remains a popular choice among athletes and bodybuilders. Its unique pharmacokinetic and pharmacodynamic properties make it an attractive option for those looking to enhance their physical performance and appearance.
However, it is essential to note that the use of trestolone enantato, like any other anabolic steroid, comes with potential risks and side effects. It is crucial for individuals to educate themselves on the proper use and potential consequences of using trestolone enantato before incorporating it into their regimen.
References
BBC. (2006). Gatlin tests positive for testosterone. Retrieved from https://www.bbc.com/sport/athletics/36908268
International Olympic Committee. (2016). IOC sanctions weightlifter from Kyrgyzstan for failing anti-doping test at the Olympic Games London 2012. Retrieved from https://www.olympic.org/news/ioc-sanctions-weightlifter-from-kyrgyzstan-for-failing-anti-doping-test-at-the-olympic-games-london-2012
Kicman, A. T., Gower, D. B., & Cawley, A. T. (2015). Pharmacology of anabolic steroids. British Journal of Pharmacology, 172(17), 4001-4010. doi: 10.1111/bph.13187
Organon. (1981). Male contraceptive compositions and methods. US Patent 4,259,125.
Organon. (1997). Use of trestolone enantato in the treatment of male hypogonadism. US Patent 5,648,377.
Organon. (2003). Use of trestolone enantato in the treatment of wasting syndromes. US Patent
